A three-year collaboration between Sheba Medical Center, Icahn School of Medicine at Mount Sinai, and NVIDIA aims to decode the 98% of the human genome that remains poorly understood by applying AI and large language models.

The project seeks to identify regulatory mechanisms that link genetic variation to disease risk and therapeutic response, advancing personalized medicine.

Statements from Rechavi, Charney, and NVIDIA representatives highlight the potential for precision medicine to transform healthcare.

The partnership was announced in mid-November 2025, and initial research is building a shared platform infrastructure.

Overall, the alliance could revolutionize genome understanding and accelerate advances in disease prevention and treatment through AI-enabled genomics.

Key participants include Prof. Gidi Rechavi of Sheba Cancer Research Center, Dr. Alexander Charney of Mount Sinai, with NVIDIA supplying AI technology and expertise.

The collaboration focuses on the remaining 98% of the genome, long dismissed as 'junk DNA,' due to its regulatory and functional elements.

An AI-driven genomic research engine will be built, integrating vast genomic datasets, AI capabilities, and clinical insights from Sheba and Mount Sinai, with NVIDIA providing the computational architecture and platforms.

Early focus areas include complex genetic regions that have slowed medical progress, with the aim of revealing disease mechanisms and potential targets.